JP2007506699A - 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 - Google Patents

良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 Download PDF

Info

Publication number
JP2007506699A
JP2007506699A JP2006527365A JP2006527365A JP2007506699A JP 2007506699 A JP2007506699 A JP 2007506699A JP 2006527365 A JP2006527365 A JP 2006527365A JP 2006527365 A JP2006527365 A JP 2006527365A JP 2007506699 A JP2007506699 A JP 2007506699A
Authority
JP
Japan
Prior art keywords
treatment
bishomo
epi
diene
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2006527365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506699A5 (fr
Inventor
アドリニ ルシアノ
コルリ エンリコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioxell SpA
Original Assignee
Bioxell SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322395A external-priority patent/GB0322395D0/en
Priority claimed from GB0325598A external-priority patent/GB2407499B/en
Priority claimed from GB0416876A external-priority patent/GB0416876D0/en
Application filed by Bioxell SpA filed Critical Bioxell SpA
Publication of JP2007506699A publication Critical patent/JP2007506699A/ja
Publication of JP2007506699A5 publication Critical patent/JP2007506699A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2006527365A 2003-09-24 2004-09-24 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用 Abandoned JP2007506699A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0322395A GB0322395D0 (en) 2003-09-24 2003-09-24 Methods for treating bladder dysfunction and related compounds and compositions
GB0325598A GB2407499B (en) 2003-11-03 2003-11-03 Vitamin D3 analogue for use in the treatment of BPH
GB0416876A GB0416876D0 (en) 2004-07-29 2004-07-29 Compound and use in treatment
PCT/EP2004/010760 WO2005027923A1 (fr) 2003-09-24 2004-09-24 Utilisation d'un analogue de vitamine d3 pour le traitement de l'hyperplasie prostatique benigne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008209429A Division JP2009035559A (ja) 2003-09-24 2008-08-18 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用

Publications (2)

Publication Number Publication Date
JP2007506699A true JP2007506699A (ja) 2007-03-22
JP2007506699A5 JP2007506699A5 (fr) 2007-10-25

Family

ID=34229055

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006527365A Abandoned JP2007506699A (ja) 2003-09-24 2004-09-24 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用
JP2008209429A Abandoned JP2009035559A (ja) 2003-09-24 2008-08-18 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008209429A Abandoned JP2009035559A (ja) 2003-09-24 2008-08-18 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用

Country Status (12)

Country Link
EP (1) EP1673096A1 (fr)
JP (2) JP2007506699A (fr)
CN (1) CN100488511C (fr)
BE (1) BE1016292A3 (fr)
BR (1) BRPI0404050A (fr)
CH (1) CH698144B1 (fr)
EA (1) EA010240B1 (fr)
FR (1) FR2859910B1 (fr)
HK (1) HK1085373A1 (fr)
NL (1) NL1027109C2 (fr)
NZ (1) NZ535531A (fr)
WO (1) WO2005027923A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038611A1 (fr) * 2004-10-05 2006-04-13 Kissei Pharmaceutical Co., Ltd. Agent pour le traitement prophylactique ou thérapeutique des troubles de collecte de l'urine dans la vessie consécutifs à l'obstruction du canal urinaire inférieur
JPWO2006038619A1 (ja) * 2004-10-06 2008-05-15 キッセイ薬品工業株式会社 前立腺肥大症に対する手術療法への移行予防用医薬組成物
US20100009949A1 (en) * 2006-03-24 2010-01-14 Bioxell S.P.A. Novel method
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
US20120164240A1 (en) 2010-12-22 2012-06-28 Audino David Lawrence Enriched a. blitoides compositions and uses thereof
US20170049834A1 (en) * 2015-08-18 2017-02-23 Golden Biotechnology Corporation Benign prostatic hyperplasia add-on therapy
FR3063906A1 (fr) * 2017-03-20 2018-09-21 Pierre Fabre Medicament Utilisation de l'oleoresine de copaifera dans les pathologies de la prostate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
TW403735B (en) * 1995-11-22 2000-09-01 Hoffmann La Roche 25-hydroxy-16-ene-26, 27-bishomo-cholecalciferol
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
EP0981523B1 (fr) * 1997-05-16 2005-12-07 Woman & Infants Hospital Composes de vitamine d3 a ether cyclique et composes de 1alpha(oh)3-epi-vitamine d3, et utilisation desdits composes
US5872113A (en) * 1997-05-16 1999-02-16 Syntex (U.S.A.) Inc. Fluorinated vitamin D3 analogs
US6255501B1 (en) * 1999-04-26 2001-07-03 Hoffman-La Roche Inc. Process for preparing antiosteoporotic agents
WO2003034961A1 (fr) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Procedes et dispositif transdermique de terazosine
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds

Also Published As

Publication number Publication date
EA010240B1 (ru) 2008-06-30
WO2005027923A1 (fr) 2005-03-31
NZ535531A (en) 2006-03-31
JP2009035559A (ja) 2009-02-19
EA200401100A1 (ru) 2005-04-28
CH698144B1 (fr) 2009-05-29
NL1027109A1 (nl) 2005-03-29
HK1085373A1 (en) 2006-08-25
NL1027109C2 (nl) 2005-05-03
FR2859910B1 (fr) 2006-04-28
EP1673096A1 (fr) 2006-06-28
BRPI0404050A (pt) 2005-06-14
CN100488511C (zh) 2009-05-20
CN1615891A (zh) 2005-05-18
BE1016292A3 (nl) 2006-07-04
FR2859910A1 (fr) 2005-03-25

Similar Documents

Publication Publication Date Title
Thiboutot et al. Update and future of hormonal therapy in acne
Jordan et al. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy
KR101850125B1 (ko) 폐경기 치료용 dhea 조성물
US20080207769A1 (en) Method for treating benign prostatic hyperplasia
JP2009035559A (ja) 良性前立腺肥大の治療のためのビタミンｄ３アナログの使用
DE602004002591T2 (de) Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
JPS62500451A (ja) ホルモン依存性がんの併用治療のための医薬組成物
TW201002330A (en) Compositions and methods for treating breast cancer
JP7046086B2 (ja) Ｍｐｃ阻害剤を使用する育毛を促進するための組成物及び方法
WO2003017973A1 (fr) Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
JP6025301B2 (ja) 治療上の使用のためのｃ−１９ステロイド
Schweikert et al. Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasia
Small et al. The selective progesterone receptor modulator ulipristal acetate inhibits the activity of the glucocorticoid receptor
JP2003534278A (ja) 抗アンドロゲン作用および抗エストロゲン作用を提供するためのビカルタミド（ｂｉｃａｌｕｔａｍｉｄｅ）およびタモキシフェン（ｔａｍｏｘｉｆｅｎ）の併用医薬品
Rasmusson et al. Therapeutic control of androgen action
CN111918657A (zh) 用于治疗物质戒断障碍的gaba-a拮抗剂
Watson et al. Hirsutism: evaluation and management
Simutis et al. Investigations on the Relationship Between Ovarian, Endocrine, and Renal Findings in Nonclinical Safety Studies of the γ-Secretase Inhibitor Avagacestat
Rodrigues-Junior et al. Effects of tamoxifen and raloxifene on body and uterine weights of rats in persistent estrus
GB2407499A (en) Compound and use in treatment
WO2022115581A1 (fr) Méthodes de traitement de l'infertilité et/ou de l'endométriose comprenant ex-527
Yahya Abdelrahman et al. Polycystic ovary syndrome in adolescents
BEhre et al. Testosterone Therapy
Muse et al. Intranasal administration (IN) of leuprolide to healthy women
Dihydrotestosterone E. NIESCHLAG. HM BEHRE

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070907

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20100210